Barboza HM

Language: Spanish
References: 7
Page: 11-16
PDF size: 83.10 Kb.

ABSTRACT

Benign Prostatic Hyperplasia is the most common benign tumor in males, Clinically it is related to age.The risk factors are not known yet; the family clinical history is very important because First-degree relatives of Benign Prostatic Hyperplasiapatients have been reported to have a relative risk four times higher than normal of developing Benign Prostatic Hyperplasia.The treatment objectives are to improve symptoms and quality of life, avoid the clinical progression of the disease and reduce the risk of complications and / or the need for surgery.

REFERENCES

1. Brenes, F et. al. (2016). Documento de consenso sobre pautas de actuación y seguimientodel varon con sintomas del tracto urinario inferior secundarios a hiperplasia prostática benigna. Sociedad española de médicos de atencion primaria. Vol.42, num.4, pags. 547-555.

2. Caja Costarricense de Seguro Social (2011). Guía de atención del cáncer de próstata. I nivel de atención. San José, Costa Rica: CCSS: 2011. pp. 14-33.

3. Carrero-Lopez, V et. al. (2016). Hiperplasia prostática benigna y síntomas del tracto urinario inferior. Revisión de las evidencias actuales. Actas Urologicas Españolas. Vol.42, num.5, pags 288-294.

4. Doherty, G. (2007). Diagnóstico y tratamiento quirúrgico. México: Manual moderno. (9naED)

5. Longo, D. (2012). Harrison principios de medicina interna. Mexico: McGraw Hill. (18vaED)

6. Morales, F (2014). Tratado de geriatría y gerontología. San José, Costa Rica: EDNASSS. (2da ED)

7. Tanagho, E. (2008). Urologia general de Smith. Mexico: Manual moderno. (14va ED). Global Iniciative for Chronic obstructive Lung Dissease (2011), Pocket guide to COPD diagnosis, management and prevention. 2011. Pág. 4-16.